Curcumin Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges
Phytotherapy Research · 2026-07 · 40 (7) · 4254-4277
DOI: 10.1002/ptr.70361 ↗At a glance
Systematische Übersicht in Phytotherapy Research, published online on 2026-04-30. Written by Siyu Lan and 4 co-authors. Institution: School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Major MEDLINE topics: Curcumin, Non-alcoholic Fatty Liver Disease, Fatty Liver. Cited 1 times so far (Crossref); 168 references. Funded by: The Sichuan Provincial Administration of Traditional Chinese Medicine, Sichuan Provincial Administration of Traditional Chinese Medicine.
Abstract (original language)
Metabolic dysfunction‐associated steatotic liver disease (MASLD), as a liver phenotype of metabolic syndrome, has a global prevalence of up to 32.4%. Its pathogenesis involves complex pathological networks, including lipid metabolism disorders, oxidative stress, inflammation, and insulin resistance. Faced with the limitations of existing single‐target drugs, curcumin, a natural polyphenolic compound, has demonstrated significant potential for the prevention and treatment of MASLD due to its multidimensional pharmacological activities, such as antioxidant, anti‐inflammatory, metabolic regulation, and mitochondrial function repair. This article provides a systematic review of recent research on curcumin therapeutic mechanisms and clinical evidence in MASLD, with a focus on its antioxidant effect, improvement of mitochondrial function, anti‐inflammatory effect, reduction of insulin resistance, and regulation of gut microbiota. It also examines the current efficacy and limitations of curcumin‐based combination therapies and their derivatives in the treatment of MASLD. As research on MASLD progresses, curcumin shows great potential for therapeutic applications. Future studies should target long‐term impacts, such as subclinical oxidative stress and epigenetic modifications. Furthermore, this article addresses persistent challenges such as curcumin's inherently low bioavailability and the lack of standardized dosing protocols, which should guide future clinical research efforts.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- R&D Center for Efficiency, Safety and Application in Chinese Materia Medica With Medical and Edible Values, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID profiles: Chaolong Rao
Funding
- The Sichuan Provincial Administration of Traditional Chinese Medicine
- Sichuan Provincial Administration of Traditional Chinese Medicine
Cite
APA
Lan, S., Zhou, X., Xiang, Y., Huang, Y., & Rao, C. (2026). Curcumin Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges. Phytotherapy Research, 40(7), 4254-4277. https://doi.org/10.1002/ptr.70361
Vancouver
Lan S, Zhou X, Xiang Y, Huang Y, Rao C. Curcumin Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges. Phytotherapy Research. 2026;40(7):4254-4277. doi:10.1002/ptr.70361
BibTeX
@article{Lan2026,
author = {Lan, Siyu and Zhou, Xinyi and Xiang, Yifei and Huang, Yan and Rao, Chaolong},
title = {Curcumin Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease: Mechanism Exploration, Clinical Application Strategies, and Application Limitations Challenges},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {7},
pages = {4254--4277},
doi = {10.1002/ptr.70361}
}
EUVIMED